Market Overview:

Paget disease is the disease where the normal function of remodeling of the bone by removing old material from bone is lost. This results is abnormally long, weak and brittle bone structure. Paget disease has no clear symptoms and individuals suffering from Paget Disease are often unaware.

Paget disease treatment is used on affect leg bones, skull, spine or pelvis and x-rays are used as a diagnosis of the disease. Paget disease treatment comprises of medications to slower the progress of the disease and if the pain persists, surgery tis recommended to realign the deformed bone.

The Paget disease can lead to further bone complications if Paget disease treatment is not unavailable and not recommended, such as arthritis, fractures and permanent deformed bone according to the American Academy of Orthopedic Surgeons.

The exact etiology of the Paget disease is yet not clear, however, researchers suggest that an individual with a Paget disease affected relative is seven times more susceptible to develop the disease than a person with no family history of Paget disease. Additionally, more than 40% of individuals receiving Paget disease treatment have a family history of the disease.

Researcher are currently focused on locating the genetic locus and studying the genes involved in the Paget disease to develop specific Paget disease treatment options. The ethical and geographical clustering of the Paget disease suggests that the prevalence of Paget disease is very high in white people or people with northern European heritage as compared to any other race.

According to the National Institutes of Health (NIH) Osteoporosis and Related Bone Diseases, Paget disease is more common in people of living in specific geographical location such as Europe, U.S., Australia and New Zealand. It is seldom reported in Asia and Africa.

The complication arising in the absence of Paget disease treatment such as arthritis and fractures are the drivers of the Paget disease treatment market. Paget disease affects about 3% to the people above the age 55 years and is more prevalent in the geriatric population.

The growing geriatric population and constant incidence of Paget disease are anticipated to be major factors influencing the expansion of Paget disease treatment market over the forecast years.

The increasing research and development in the developed countries on Paget disease treatment options coupled with the growing biotechnology research expenditure will account as compellers for the growth of Paget disease treatment options in the market.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Market Segmentation:

Route of administration	Oral Intravenous Topical
Treatment type	Actonel Reclast Zoledronic Acid Fosamax Miacalcin Aredia Calcitonin Zometa Others
Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies Drug Stores
Region	North America Latin America Europe Asia Pacific Middle East & Africa